Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia

Kalifa Bojang, Paul Milligan, Margaret Pinder, Tom Doherty, Amanda Leach, Opokua Ofori-Anyinam, Marc Lievens, Kent Kester, Kurt Schaecher, Ripley Ballou, Joe Cohen

    Research output: Contribution to journalArticle

    Original languageEnglish
    Pages (from-to)242-247
    Number of pages6
    JournalHuman Vaccines
    Volume5
    Issue number4
    DOIs
    Publication statusPublished - 2009

    Cite this